Daniel R. Passeri

Daniel R. Passeri

Former Chief Executive OfficeratCue Biopharma· In proxies 2022–2025

Pay in FY2025+2% from the year before · Cue Biopharma stock -72.0% the same year

Daniel R. Passeri was paid $1.4M in FY2025 (Dec), up 2%. Cue Biopharma stock fell 72.0% that year.

Pay$100 in the stock at the end of FY21 → $3
Pay is from the Summary Compensation Table of each Cue Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cue BiopharmaPublic company · 4 yr
    • Former Chief Executive Officer2022 – Present · 4 yrStock in role -94%
  2. Curis, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?